Semaglutide denied for failing step therapy by Cigna?
Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.
At a glance
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
BMI >=30, OR BMI >=27 with comorbidity. 6-month lifestyle modification documented. Continuation requires >=5% weight loss at 6 months.
What works in the appeal
Sub-27 with severe comorbidity: ABCD (AACE 2023) supports pharmacotherapy for BMI 25-27 with severe complications. Lifestyle: WW, Noom, Optavia, Profile, physician-supervised programs all qualify. Continuation <5%: argue HbA1c improvement, BP, waist circumference, AHI reductions.
The Cigna angle on Semaglutide
Cigna's step-therapy on semaglutide under CP 1013 requires documented trial of phentermine/topiramate (Qsymia) or naltrexone/bupropion (Contrave) before approval, or a documented contraindication. The denial fires most often because prior trial documentation lacks dose, duration, or outcome.
For each prior agent, the appeal needs explicit documentation:
- Drug + brand. Cigna distinguishes Qsymia from phentermine alone. Qsymia (full strength 15/92mg) is preferred for the step because it's the higher-efficacy combination. Name the brand in the chart note explicitly.
- Dose: Qsymia 15/92mg target, Contrave 32/360mg target, phentermine 37.5mg.
- Duration: ≥3 months at full dose.
- Outcome: Percent weight loss at 3 months. Cigna treats <5% as treatment failure.
Contraindications Cigna accepts without trial:
- Phentermine: uncontrolled hypertension, MI/stroke/heart failure history, hyperthyroidism, glaucoma, MAO-inhibitor use, pregnancy.
- Contrave: seizure disorder, bulimia/anorexia, active opioid use, severe hepatic impairment.
- Qsymia: kidney stones, metabolic acidosis, glaucoma, hyperthyroidism, MAO-inhibitor use.
A Cigna-specific quirk: Cigna sometimes counts intensive lifestyle programs as a step. If the patient completed Form Health, Noom Med, WeightWatchers Clinical, or a hospital-based comprehensive program without ≥5% loss at 6 months, document as a prior step. This works on Cigna better than on UHC because Cigna's CP 1013 has language recognizing comprehensive programs.
For patients switching from a different GLP-1 (liraglutide, dulaglutide, exenatide), Cigna's policy treats class-failure (inadequate response or intolerable side effects despite dose titration) as satisfying step therapy. Document the prior GLP-1 trial dates and reason for discontinuation.
The federal regulatory hook: step-therapy override under 29 USC §1185d for ERISA plans when continuation of current therapy is medically appropriate. Texas Insurance Code §1369.0541, Illinois 215 ILCS 5/356z.21, NY Public Health Law §270-a, California SB-159 provide stronger override protections for fully-insured plans than federal ERISA — confirm plan type before drafting.
The Cigna-specific procedural lever: Cigna's pharmacy benefit runs through Express Scripts on most plans. The exception process runs through Express Scripts' formulary committee, not Cigna's medical review. Submitting the appeal through Cigna's medical channel routes it incorrectly and adds 30 days. Always verify the right channel before submission — pull from the patient's pharmacy ID card.
Closing tactical tip: Cigna's ESI step-therapy override has a 72-hour expedited path under ERISA §503(f)(2)(i) — request expedited review explicitly if the patient is currently on a stable regimen and is at risk of treatment interruption.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →